SynCrest Inc., a peptide and nucleotide CRDMO (contract research, development and manufacturing organization) joint venture between Otsuka Chemical Co., Ltd., and Yokogawa Electric Corp., announced its services are now available for pharmaceutical companies and research institutions in Japan, Europe, North America, and South America.
MARLBOROUGH, Mass. & PRINCETON, N.J.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD). In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder (MDD).
The artificial intelligence-powered drug designer Schrödinger is growing its to-do list, with two Big Pharma collaborations focused in neuroscience.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that AJOVY® Subcutaneous Injection 225 mg Syringe (generic name is fremanezumab) will be launched in Japan for the indication of preventive treatment of migraine in adult patients. It will become available from August 30, 2021.
Japanese drugmaker Otsuka Pharmaceutical today announces it has received regulatory approval in Japan for a once-daily form in pediatric patients of Busulfex (busulfan) Injection 60mg.
Indian firm MSN Labs has won US approval for its generic injectables decitabine and fosaprepitant, through its American subsidiary Novadoz Pharmaceuticals. The antiemetic fosaprepitant is a competitor to Merck & Co’s branded option Emend, and will begin shipping immediately.
Otsuka has some good news to report on the other drug that it obtained in the $886 million acquisition of Astex Pharmaceuticals. ASTX727 combines the chemotherapy decitabine with cedazuridine, an oral inhibitor of cytidine deaminase. A Phase III study evaluating the combo and intermediate to high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia met its primary endpoint, the company said.
Otsuka Chemical Co., Ltd has announced its acquisition on cefixime business from Astellas Pharma, Inc. on 5 June 2019, in Tokyo, Japan. Through this agreement, Otsuka Chemical acquires the cefixime business of Astellas Pharma to supply the API (active pharmaceutical ingredient) to licensees abroad together with assets such as contracts belonging to the licensing company and the commercial brand. This implies the entry of the company into the API business, which strengthens the business related to antibiotics integrated from intermediaries to API.
Lundbeck’s Dunsire has something to cheer as Rexulti combo shows promise in PTSD
WASHINGTON, Nov. 16, 2018 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global leader in the development of digital and traditional treatments for mental illness, together with honorary co-host U.S. Representative Bonnie Watson Coleman (NJ-12) hosted a roundtable discussion of the expanding role of technology in the future of healthcare and its potential to break down barriers to care and support patient outcomes.